Trials / Completed
CompletedNCT03895515
Effect of Fiasp® in Type 1 Diabetes Treatment
The Effect of Fiasp® (Fast-acting Insulin Aspart) in Type 1 Diabetes Patients Using Continuous Glucose Monitoring / Flash Glucose Monitoring in Real-world Clinical Practice in Sweden. A Non-interventional, Retrospective Chart and Database Review Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 178 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Fiasp® is a meal-time insulin that has been available in Sweden since June 2017. This study will investigate the effectiveness of Fiasp® in treating Type 1 Diabetes Mellitus. The study will be based on blood sugar measurements that the participants have uploaded to the Diasend® database and on existing data in their electronic medical records. The study does not require any additional visits to the study doctor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fiasp® | Participants receive treatment with Fiasp® according to routine clinical practice. All treatment decisions, including assignment of participants to Fiasp® treatment, were made independently of the study and prior to the participants' inclusion in the study. |
Timeline
- Start date
- 2020-01-03
- Primary completion
- 2020-12-21
- Completion
- 2020-12-21
- First posted
- 2019-03-29
- Last updated
- 2022-04-07
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT03895515. Inclusion in this directory is not an endorsement.